On the Radar: Five high-value biotech stocks

Our new On the Radar report returns with fresh insights from Simos Simeonidis, PhD, Rodman & Renshaw's senior biotech analyst, who highlights biotech stocks which he believes will be good value

Lilly bets another $375M on Zymeworks' two-pronged cancer tech

Eli Lilly is expanding its relationship with Canadian biotech Zymeworks, signing a broader deal that promises up to $375 million in milestones for its partner as the two collaborate on cancer immunotherapies.

Lilly, Zymeworks Announce Expansion of Strategic Licensing and Collaboration Agreement

INDIANAPOLIS and VANCOUVER, British Columbia -- Eli Lilly and Company (NYSE: LLY) and Zymeworks Inc. today announced the expansion of their existing licensing and collaboration agreement. Originally...

Celgene adds $1B-plus immuno-oncology deal, buyout option for Sutro

Close to two years after Celgene closed its first development deal with Sutro Biopharma, the prolific partnering machine at the big biotech has come back and taken an option on buying the company and its antibody-drug conjugates and bispecifics. And Celgene is expanding their collaboration to include immuno-oncology drugs, the hottest R&D field in biotech.

J&J heads to Texas with its R&D farm system, scouting for biotech startups

Johnson & Johnson is expanding its network of biopharma incubators, taking to Texas with a plan to host as many as 50 local biotech startups.

Johnson & Johnson Innovation Announces New J-Labs Incubator at Texas Medical Center

J-Labs @TMC Will Be a Core Component of the Texas Medical Center's Innovation Institute HOUSTON, October 23, 2014 -- Johnson & Johnson Innovation, LLC., today announced plans to expand...

Sutro Biopharma and Celgene Corporation Enter Multi-Year Strategic Collaboration and Option to Acquire Agreement

Deal Expands Immuno-Oncology Product Discovery and Development Program and Aims to Accelerate Development of Oncology Therapeutics with Compelling Patient Benefit SOUTH SAN FRANCISCO, Oct 23, 2014...

Pfizer, Novartis chip in on $17M round for an Atlas upstart focused on pain

The busy partners at Atlas Venture have gathered together a $17 million Series A for their latest biotech creation: Quartet Medicine, which pairs together two scientific founders who have been exploring the frontiers of pain management. This is Atlas' fourth maiden round for one of their biotech launches in a little more than a week, with Cambridge, MA-based Quartet joining Unum, Raze and Bicycle in a rare streak of startups. And there are likely some more to come.

Lexicon inks a $145M pact with Ipsen; Boehringer launches PhIII nintedanib study for colorectal cancer;

@FierceBiotech: Viamet drops IPO, spins out cancer drug as ex-Elan chief funds $60M round. More | Follow @FierceBiotech @JohnCFierce: Kelly Martin (Elan) is ba-a-a-ack. Viamet drops IPO, spins out...

Proteon banks $61M in a down-sized IPO as it moves on without Novartis

Proteon Therapeutics priced its IPO below its expected range, clearing $61 million to pay the way for its investigational vascular drug.